#United States #biopharmaceuticals #Ibezapolstat #Staten Island #Acurx Pharmaceuticals

Acurx Pharmaceuticals Secures $2.67 Million: A Step Forward in Antibiotic Development

Acurx Pharmaceuticals, Inc., a biopharmaceutical firm focused on pioneering novel antibiotics for challenging bacterial infections, has recently announced a significant milestone in its funding strategy. The company has entered into a warrant inducement agreement that will yield approximately $2.67 million in gross proceeds. This agreement involves the exercise of existing warrants held by an investor which will enhance Acurx's financial resources as it advances its innovative drug pipeline.

Inducement Agreement Details

On June 17, 2025, Acurx revealed that it has struck an agreement with a holder of its existing warrants, allowing this individual to exercise warrants for common stock at a drastically reduced price of $0.675 per share. These warrants, originally issued in July 2022 and May 2023, had exercise prices ranging between $3.25 to $3.26, indicating a substantial discount that incentivizes the holder to convert investments into immediate cash for the company. In return for this cash exercise, the investor will receive new warrants that can be exercised at an immediate price of $0.425 per common share – an attractive prospect for future investment returns.

The New Warrants Structure

The new warrant issuance structure refers to two distinct categories: G-1 warrants and G-2 warrants. Specifically, a total of 8,890,870 shares are available through these new warrants where:

• - The G-1 warrants allow immediate exercise and remain valid for five years.
• - The G-2 warrants will require shareholder approval for exercise, but hold the same five-year expiration timeframe.

Notably, the shares issued through this transaction will utilize existing effective registration statements; meaning that investors can trade these securities under the regulatory framework established by the Securities Act of 1933.

Financial Use of Proceeds

Acurx has indicated that these funds will be allocated for working capital and general operational costs as it pushes forward in its mission to develop significant new antibiotics. This move comes at a critical time as the necessity for effective treatments against bacterial infections continues to grow globally.

Focus on Ibezapolstat

A prominent highlight in Acurx's research is Ibezapolstat, the company’s leading antibiotic candidate, which is transitioning into Phase 3 clinical trials aimed at treating patients suffering from Clostridioides difficile infections (CDI). Ibezapolstat has already garnered significant attention, having received the FDA’s designation as a Qualified Infectious Disease Product (QIDP), paving the way for accelerated development under the GAIN Act incentives. Furthermore, it holds a Fast Track designation from the FDA, accelerating its journey through the regulatory processes.

The unique mechanism of Ibezapolstat as a Gram-Positive Selective Spectrum (GPSS®) antibacterial is a significant advance in antibiotic research, highlighting its potential to maintain healthy microbiomes while effectively targeting harmful bacteria. This is particularly relevant as the CDC has classified C. difficile infections as an urgent threat necessitating new therapeutic options.

A Look Ahead

With the recent actions to increase liquidity, Acurx Pharmaceuticals is poised to strengthen its clinical and commercial initiatives significantly. The expedited development of Ibezapolstat, combined with the funded efforts from warrant exercises, creates a promising landscape for upcoming trials and eventual market introduction. The company aims to increase its impact in the field of infectious disease treatment as it tackles the challenges posed by resistant bacterial strains.

Acurx's ambitious approach provides hope not only for investors but also for the many patients around the world in need of effective antibiotics. As they navigate through the complexities of biopharmaceutical development, Acurx stands at the forefront of innovative solutions to public health dilemmas.

For more information about Acurx Pharmaceuticals and its product pipeline, visit www.acurxpharma.com.